Several studies have focused on VEGF measurements within the platelets because of three principal reasons: (a) platelets are considered the major physiological transporter of VEGF in blood [2, 40]; (b) peripheral blood platelets of cancer patients carry more VEGF than platelets of normal controls [12, 39, 41]; (c) platelets are actively infiltrated to solid tumors and have a relevant role in tumor angiogenesis [42, 43, 44]. The gene discussed is VEGFA; the disease is neoplasm.